Table 1.

Clinical Characteristics of Controls and METSYN Subjects

Controls (n = 16)METSYN (n = 18)P Value
GenderF (10), M (6)F (9), M (9)NS
Age43 ± 346 ± 3NS
Body mass index, kg/m223 ± 0.535 ± 2b<.001
Waist circumference, cm<102 (M)135 ± 18 (M)a<.01
<88 (F)109 ± 5 (F)a<.01
Systolic BP, mm Hg112 ± 2131 ± 5b<.001
    BP medications(8)
Diastolic BP, mm Hg70 ± 278 ± 3a<.01
Fasting blood glucose, mg/dL88 ± 298 ± 3b<.005
Total cholesterol, mg/dL191 ± 10196 ± 9NS
    LDL cholesterol, mg/dL123 ± 9128 ± 8NS
        Statin treatment(5)
    HDL cholesterol, mg/dL57 ± 346 ± 2a<.01
        HDL <40, M(5)
        HDL <50, F(5)
    Triglycerides, mg/dL70 ± 7124 ± 10b<.001
Baseline insulin, mU/L2.7 ± 0.511.3 ± 2.6b<.001
Baseline FFAs, mEq/L0.68 ± 0.040.93 ± 0.06b<.002
Controls (n = 16)METSYN (n = 18)P Value
GenderF (10), M (6)F (9), M (9)NS
Age43 ± 346 ± 3NS
Body mass index, kg/m223 ± 0.535 ± 2b<.001
Waist circumference, cm<102 (M)135 ± 18 (M)a<.01
<88 (F)109 ± 5 (F)a<.01
Systolic BP, mm Hg112 ± 2131 ± 5b<.001
    BP medications(8)
Diastolic BP, mm Hg70 ± 278 ± 3a<.01
Fasting blood glucose, mg/dL88 ± 298 ± 3b<.005
Total cholesterol, mg/dL191 ± 10196 ± 9NS
    LDL cholesterol, mg/dL123 ± 9128 ± 8NS
        Statin treatment(5)
    HDL cholesterol, mg/dL57 ± 346 ± 2a<.01
        HDL <40, M(5)
        HDL <50, F(5)
    Triglycerides, mg/dL70 ± 7124 ± 10b<.001
Baseline insulin, mU/L2.7 ± 0.511.3 ± 2.6b<.001
Baseline FFAs, mEq/L0.68 ± 0.040.93 ± 0.06b<.002

Abbreviation: LDL, low-density lipoprotein. Values are mean ± SEM.

a

, P < .01;

b

, P < .001.

Table 1.

Clinical Characteristics of Controls and METSYN Subjects

Controls (n = 16)METSYN (n = 18)P Value
GenderF (10), M (6)F (9), M (9)NS
Age43 ± 346 ± 3NS
Body mass index, kg/m223 ± 0.535 ± 2b<.001
Waist circumference, cm<102 (M)135 ± 18 (M)a<.01
<88 (F)109 ± 5 (F)a<.01
Systolic BP, mm Hg112 ± 2131 ± 5b<.001
    BP medications(8)
Diastolic BP, mm Hg70 ± 278 ± 3a<.01
Fasting blood glucose, mg/dL88 ± 298 ± 3b<.005
Total cholesterol, mg/dL191 ± 10196 ± 9NS
    LDL cholesterol, mg/dL123 ± 9128 ± 8NS
        Statin treatment(5)
    HDL cholesterol, mg/dL57 ± 346 ± 2a<.01
        HDL <40, M(5)
        HDL <50, F(5)
    Triglycerides, mg/dL70 ± 7124 ± 10b<.001
Baseline insulin, mU/L2.7 ± 0.511.3 ± 2.6b<.001
Baseline FFAs, mEq/L0.68 ± 0.040.93 ± 0.06b<.002
Controls (n = 16)METSYN (n = 18)P Value
GenderF (10), M (6)F (9), M (9)NS
Age43 ± 346 ± 3NS
Body mass index, kg/m223 ± 0.535 ± 2b<.001
Waist circumference, cm<102 (M)135 ± 18 (M)a<.01
<88 (F)109 ± 5 (F)a<.01
Systolic BP, mm Hg112 ± 2131 ± 5b<.001
    BP medications(8)
Diastolic BP, mm Hg70 ± 278 ± 3a<.01
Fasting blood glucose, mg/dL88 ± 298 ± 3b<.005
Total cholesterol, mg/dL191 ± 10196 ± 9NS
    LDL cholesterol, mg/dL123 ± 9128 ± 8NS
        Statin treatment(5)
    HDL cholesterol, mg/dL57 ± 346 ± 2a<.01
        HDL <40, M(5)
        HDL <50, F(5)
    Triglycerides, mg/dL70 ± 7124 ± 10b<.001
Baseline insulin, mU/L2.7 ± 0.511.3 ± 2.6b<.001
Baseline FFAs, mEq/L0.68 ± 0.040.93 ± 0.06b<.002

Abbreviation: LDL, low-density lipoprotein. Values are mean ± SEM.

a

, P < .01;

b

, P < .001.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close